Potent modulation of the CepR quorum sensing receptor and virulence in a Burkholderia cepacia complex member using non-native lactone ligands by Slinger, Betty L. et al.
1Scientific RepoRtS |         (2019) 9:13449  | https://doi.org/10.1038/s41598-019-49693-x
www.nature.com/scientificreports
potent modulation of the cepR 
quorum sensing receptor and 
virulence in a Burkholderia cepacia 
complex member using non-native 
lactone ligands
Betty L. Slinger1, Jacqueline J. Deay  2, Josephine R. chandler2 & Helen e. Blackwell1
the Burkholderia cepacia complex (Bcc) is a family of closely related bacterial pathogens that are the 
causative agent of deadly human infections. Virulence in Bcc species has been shown to be controlled 
by the cepi/cepR quorum sensing (QS) system, which is mediated by an N-acyl L-homoserine lactone 
(AHL) signal (c8-AHL) and its cognate LuxR-type receptor (cepR). chemical strategies to block QS in 
Bcc members would represent an approach to intercept this bacterial communication process and 
further delineate its role in infection. in the current study, we sought to identify non-native AHLs 
capable of agonizing or antagonizing cepR, and thereby QS, in a Bcc member. We screened a library 
of AHL analogs in cell-based reporters for CepR, and identified numerous highly potent CepR agonists 
and antagonists. these compounds remain active in a Bcc member, B. multivorans, with one agonist 
250-fold more potent than the native ligand C8-AHL, and can affect QS-controlled motility. Further, 
the cepR antagonists prolong C. elegans survival in an infection model. These AHL analogs are the first 
reported non-native molecules that both directly modulate cepR and impact QS-controlled phenotypes 
in a Bcc member, and represent valuable chemical tools to assess the role of QS in Bcc infections.
Members of the Burkholderia cepacia complex (Bcc) have emerged as multi-drug resistant opportunistic patho-
gens in human infections, including pulmonary infection associated with cystic fibrosis (CF)1 and central nerv-
ous system infections2. The Bcc consists of more than 17 closely-related species that are mostly found in the 
environment and has grown to include not only plant, animal, and human pathogens, but also bioremediation 
and biocontrol strains. While all Bcc members have the potential to infect CF patients3, the most commonly 
isolated species from these patients are B. cenocepacia and B. multivorans4. Infections are especially problematic 
due to these species having high levels of intrinsic and acquired resistance to many clinically-relevant antibiotics 
(recently reviewed in ref.5). Furthermore, promising new antibiotics for the Bcc, such as Q226, were subsequently 
shown to increase resistance after treatment and had toxicity effects in the host7. Consequently, new therapeutic 
strategies are needed to treat Bcc infections.
Because pathogenicity and virulence phenotypes are under the control of quorum sensing (QS) in many com-
mon bacterial pathogens, including the Bcc, QS inhibition has attracted interest as a potential strategy to com-
bat bacterial infections8. Quorum sensing (QS) is a bacterial cell-cell signaling system based on small molecule 
or peptide signals, termed autoinducers. Proteobacteria commonly use diffusible N-acyl L-homoserine lactone 
(AHL) autoinducers, which are generated by LuxI-type synthases and sensed by cytoplasmic LuxR-type receptors. 
Signal concentration increases with cell density, and when a threshold population is achieved in a given environ-
ment, the QS signal will productively bind to its target receptor protein. This binding event will ultimately cause 
alterations in gene expression levels, allowing the bacteria to initiate group-beneficial behaviors. QS allows path-
ogens to coordinate production of factors that increase infectivity (e.g., toxins, exoenzymes, and biofilm matrix 
components)9. There is evidence to suggest that targeting the QS system may put less selective pressure on these 
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pathogens and could avoid the development of resistant bacteria10. Therefore, QS systems have been proposed as 
promising targets for the development of new anti-infective compounds11.
All of the members of the Bcc investigated so far contain the CepI/CepR QS system, which synthesizes and 
responds to the autoinducer N-octanoyl L-homoserine lactone (C8-AHL, Fig. 1) via the CepI synthase and CepR 
receptor, respectively. QS is a central regulator for the expression of pathogenic traits in the Bcc12, and the CepI/
CepR circuit has been demonstrated to control virulence in various eukaryotic models of Bcc infection, including 
C. elegans13, fruit fly (D. melanogaster)14, rats, and mice15,16. Furthermore, a functional QS system is maintained in 
chronic B. cenocepacia and B. multivorans CF-infections17, which is intriguing because the related LasR receptor 
from the most commonly isolated CF-pathogen, Pseudomonas aeruginosa, can become non-functional during 
the course of chronic CF-infections18–20. This result underscores the likely importance of the CepI/CepR system 
to Burkholderia physiology and Bcc pathogenicity.
Methods to inhibit QS in the Bcc could be extremely valuable for both fundamental studies of the CepI/
CepR system and for infection control. In addition, strategies that selectively target CepR in a mixed micro-
bial setting could illuminate the role of possible interspecies interactions via QS in polymicrobial infections 
or environments. Small molecules that agonize or antagonize CepI/CepR would represent one such strategy. 
Our laboratory has developed hundreds of synthetic AHLs and non-AHL-derived compounds that can either 
inhibit or activate LuxR-type receptors in many different species of Gram-negative bacteria. For example, 
these compounds have proven successful at modulating QS in P. aeruginosa (ligands targeting LasR, RhlR, or 
QscR)21,22, Acinetobacter baumannii (AbaR)23, Agrobacterium tumefaciens (TraR)24,25, Vibrio fischeri (LuxR)25, 
Chromobacterium violaceum (CviR)26, Pectobacterium carotovora (ExpR1 and ExpR2)27, Pseudomonas syringae 
(AhlR)28, and Rhodopseudomonas palustris (RpaR)29. In the work outlined herein, we sought to apply our research 
strategy to identify chemical modulators of CepR and utilize these ligands to modulate QS, and thereby virulence, 
in a member of the Bcc.
To date, there has been limited research focused on developing compounds that target the CepI/CepR sys-
tem, or modulate QS in general, in Bcc member species. In fact, we are only aware of five reported studies30–34. 
An early report by Weingart et al. provided some clues as to which structural features of naturally-occurring 
AHLs may affect CepR function30, and identified hexanoyl-HL and 5-hexynoyl-HL as having slight inhibitory 
effects on CepR at concentrations greater than 1 μM, although potency data (i.e., EC50 and IC50 values) were not 
reported. More recently, Scoffone and coworkers reported several diketopiperazine derivatives were CepI syn-
thase inhibitors and increased survival of B. cenocepacia-infected Caenorhabditis elegans35. Other compounds 
have been shown to affect QS-controlled phenotypes in certain Bcc members. For example, Riedel and coworkers 
demonstrated that a hydrazide type compound (termed compound 3), could alter QS-controlled phenotypes in 
B. cenocepacia H11133. In addition, Brackman and colleagues discovered that two different compounds, baicalin 
hydrate32 and a triazole compound34, can reduce biofilm biomass (a QS-controlled phenotype) in B. cenocepacia 
and B. multivorans. However, in all of these studies, the molecular target of the compounds was not demonstrated, 
and it was subsequently discovered that baicalin hydrate likely targets bacterial respiration (not QS)36. These prior 
studies indicate that additional research is required to identify chemical tools to selectively target CepR.
Herein, we report the systematic screening of an AHL-based library in an E. coli CepR reporter strain and the 
discovery of a set of highly potent CepR modulators. The CepR antagonists have sub- to single-digit micromolar 
IC50 values and many of the CepR agonists are more potent than CepR’s native ligand, C8-AHL, with EC50 values 
below 1 nM in the reporter strain. These compounds remain active in a member of the Bcc, B. multivorans, and 
affect QS-controlled motility, with antagonists reducing motility by roughly 50%. Notably, our lead CepR antago-
nists increase the survival of C. elegans colonized by B. multivorans, suggesting that B. multivorans pathogenicity 
was attenuated by targeting CepR and inhibiting QS-controlled pathways. Scrutiny of the lead ligands allowed 
us to develop the first structure-activity relationships (SARs) for AHL-mediated CepR antagonism and agonism, 
which will provide a launching point for the design of yet more potent and potentially receptor selective ligands 
Figure 1. Simplified QS circuit in Bcc bacteria. The CepI synthase (pink) produces the diffusible N-octanoyl 
L-homoserine lactone (C8-AHL, black star) at a low basal level. With population growth or bacterial 
confinement, signal concentration will reach a threshold intracellular level upon which C8-AHL will bind 
the CepR receptor (green), potentially induces receptor homodimerization, and turns on expression of QS-
controlled genes. Lighter and darker green portions of CepR indicate the putative ligand and DNA binding 
domains, respectively.
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for CepR. These compounds represent valuable new chemical tools to study the role of CepR and QS in the vir-
ulence of Bcc members.
Results
Selection of compounds for testing. Our laboratory has previously reported the design, synthesis, and 
evaluation of several libraries of native AHLs, non-native AHL, and AHL-like compounds22,25,26,37. We turned 
to these in-house libraries to identify modulators of CepR in the Bcc (see Fig. S1 for structures of the selected 
169 compounds). The majority of these compounds contained a lactone “head group” with a variety of acyl “tail 
groups” that could presumably occupy the same space as C8-AHL in the CepR ligand-binding site, and thereby 
act as competitive agonists or antagonists.
Development of an E. coli β-galactosidase reporter for cepR. We began our study by screening the 
AHL library for CepR modulators using an E. coli-based two plasmid reporter system (Ec-reporter)38–40. Certain 
members of the Bcc harbor additional QS systems that are either AHL-based (e.g., BviI/BviR in B. vietnamien-
sis)41 or diffusible signal factor (DSF)-based (B. cenocepacia)42, and at least one member of the Bcc has multiple 
receptors that respond to C8-AHL (e.g., CepR and CepR2 in B. cenocepacia)43. Thus, we reasoned that using a 
CepR reporter in a heterologous background could simplify our initial analyses. We modified our previously 
reported E. coli-based two plasmid β-galactosidase reporter system to develop a CepR Ec-reporter (see Methods). 
The first plasmid, pJN105-cepR, contains CepR from B. cenocepacia under the control of the L-arabinose induc-
ible pBAD promoter. A second plasmid contains a transcriptional fusion of lacZ to the cepI promoter region. 
The two plasmids were co-transformed into a QS mutant E. coli strain (JLD271 ∆sdiA) that lacks its LuxR-type 
receptor, SdiA. Using this reporter system, if an exogenously -added compound is able to interact with CepR, this 
will affect the protein’s interaction with the cepI promoter region and alter β-galactosidase production. Enzyme 
production, and thereby CepR activity, is then measurable via the degradation of a colorimetric substrate for 
β-galactosidase. Using this new Ec-reporter, we observed robust activity of CepR in response to its native ligand 








C4-AHL 23 — —
C6-AHL 87 ≥20000c —
C8-AHL 100 5.7 4.6–6.9
3’OH-C8-AHL 84 210 160–280
3’O-C8-AHL 86 1200 720–2500
D-3’O-C8-AHL 85 ≥27000c —
C10-AHL 87 110 83–140
C12-AHL 98 310 180–520
C14-AHL 49 — —
C16-AHL 35 — —
A11 −5.0 — —
A12 46 — —
A13 110 150 100–240
B7 97 0.29 0.14–0.59
B9 88 1000 590–2100
B11 87 130 85–200
E26 96 5.9 3.5–10
E28 92 3.8 1.7–8.2
E29 92 2.3 0.75–5.7
E30 85 4.4 3.0–6.4
E31 89 4.4 2.1–9.6
E32 97 1.1 0.75–1.7
E33 92 0.95 0.070–3.5
E34 100 0.071 0.029–0.13
E35 100 0.18 0.10–0.33
E36 92 26 15–48
E37 95 0.19 0.13–0.26
E38 93 660 380–1100
E39 100 1.4 0.49–3.4
Table 1. CepR agonism data for selected compounds in the E. coli reportera. aCompounds were evaluated in E. 
coli reporter strain JLD271 [pJN105-cepR + pSC11-cepI]. Activity for 100 μM C8-AHL set to 100%. All assays 
n ≥ 3. Maximal activation error = ±10%. See Methods for full details of assay methods. bCI = 95% confidence 
interval for EC50 value. cDose-response curve did not reach maximum plateau.
4Scientific RepoRtS |         (2019) 9:13449  | https://doi.org/10.1038/s41598-019-49693-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
Regarding our choice of CepR for this Ec-reporter, B. cenocepacia is among the most common Bcc-isolate 
from CF patients44. Further, there is high sequence similarity among both the cepI promoter sequences and the 
CepR protein sequences in Bcc member species (~76% and ~95%, respectively; Fig. S3), and the lux box is 100% 
conserved, suggesting compounds identified for CepR in B. cenocepacia will be effective in targeting CepR from 
other Bcc member species.
cepR agonism results in the ec-reporter. We used the CepR Ec-reporter to perform a primary agonism 
screen at a single compound concentration (100 μM, or its solubility limit, indicated in Table S1). Thirty-one 
compounds displaying ≥70% agonistic activity in CepR (relative to C8-AHL) were identified and subjected 
to dose-response analyses using the Ec-reporter (Table I; see Table S2 for complete screening data and Fig. S3 
for dose-response curves). We focus our analyses here on the most potent CepR agonists found in these 
dose-response studies.
Overall, the most potent class of CepR agonists were phenylpropionyl homoserine lactones (PPHLs). In fact, 
11 PPHL compounds were more potent agonists than C8-AHL, CepR’s native ligand (E34 > E35 ≈ E37 > B7 > E3
3 > E32 ≈ E39 > E28 > E30 ≈ E31 > C8-AHL; Table 1). Strikingly, we found PPHL E34, with a para-methylsulfide 
substituent, was nearly 100-fold more potent than C8-AHL (Act % = 104, EC50 = 0.07 nM) in the Ec-reporter. 
Other notable CepR agonists that had sub-nanomolar potencies were E35, E37, B7, and E33. Overall, we found 
para-substituted PPHLs to be more potent than their meta-substituted analogs. For example, para-nitro PPHL 
E37 was a more potent agonist than its meta-substituted analog E38 (EC50 values of 0.19 nM vs. 660 nM, respec-
tively), and this trend held true for E35 vs. E36, and B7 vs. E31, among others (Tables 1 and S1). Interestingly, 
these PPHL-type CepR agonists contained varied types of aryl substituents. Electron withdrawing groups, such 
as a nitro (E37) or trifluoromethyl (E35) group yielded potent agonists, as did electron donating groups, such as 
methoxy (E28) or methyl (E26) groups. However, it appears that some kind of substituent on the aryl group is 
necessary for potent CepR agonism, as the non-substituted PPHL (B9) had an EC50 ~1000 fold higher than those 
for substituted PPHLs. Replacement of the aryl group with a bulkier cyclohexyl group (to give B11) did lead to 
an increase in potency relative to B9, suggestive that sterics may be more important than electronics in this set of 
CepR agonists.
These assay data suggest that, out of the compounds screened, the PPHL scaffold is ideal for CepR activation, 
perhaps as it shares a similar tail length as the native ligand C8-AHL (~8 atoms). We observed that the incor-
poration of more or less atoms in the tail dramatically reduced compound potency. AHLs with 6, 10, and 12 
carbons in the acyl chain only weakly to moderately activated CepR relative to C8-AHL (C6-AHL, Act % = 87, 
EC50 ≥ 20000 nM; C10-AHL, Act % = 87, EC50 = 109 nM; and C12-AHL: Act % = 98, EC50 = 310 nM; Table S2), and 
longer acyl chain lengths were inactive (i.e., C14-AHL and C16-AHL). In most cases, compounds with tail lengths 
shorter than C8-AHL, for example, C4-AHL and C6-AHL, were considerably less agonistic and were actually 
CepR antagonists instead (see below).
The agonism assay data provided additional insights into CepR’s preference for AHL-type agonists. In con-
gruence with previous findings for other LuxR-type receptors25, the stereochemistry of the lactone ring was key to 
CepR activation, as compound B1, the D-isomer of C8-AHL, was inactive (Table S2). Sulfonamide AHL analogs 
also failed to activate CepR (i.e., A11, A12, and A13) and were found to antagonize CepR instead (see below; 
Table 2 and Fig. S3). Lastly, we found that a methylene at the 3-position of the acyl tail (as opposed to a 3-OH or 
3-oxo) allowed for maximal CepR activation and potency (C8-AHL, Act % = 100, EC50 = 5.7 nM; 3’OH-C8-AHL, 
Act % = 84, EC50 = 210 nM; and 3’O-C8-AHL, Act % = 87, EC50 = 1200 nM; Table 1 and S2). None of the 20 lead 
CepR agonists were oxidized at carbon 3 of the tail.
cepR antagonism results in the ec-reporter. To identify antagonists of CepR, we screened the AHL 
library (at 100 μM) in competition against the native ligand C8-AHL (at approximately twice its EC50 value, 0.01 
μM) in the Ec-reporter. We found numerous strong CepR antagonists in the initial screen, with 23 compounds 
exhibiting ≥50% inhibition of CepR activity. The active compounds were subjected to dose-response analyses in 
the Ec-reporter to obtain IC50 values and assess their relative potencies (Table 2; see Table S3 for complete screen-
ing data and Fig. S3 for dose-response curves). One general trend that we noted at the outset was the majority of 
the antagonists had acyl tails of similar or shorter overall length than CepR’s native ligand, C8-AHL. From this 
set, the strongest antagonists could be divided into two classes: (i) “short alkyl tail” AHLs or analogs thereof, and 
(ii) phenylacetanoyl HLs (PHLs). The discovery that the latter compounds were CepR antagonists was perhaps 
not surprising, as we have found substituted PHLs to strongly antagonize the majority of the LuxR-type receptors 
studied in our laboratory to date22,24,29,45,46. Interestingly, the unsubstituted PHL, C1, was recently reported to be 
the natural AHL signal used by the prosthecate bacterium, Prosthecomicrobium hirschii47.
The most potent CepR antagonists in the short-alkyl tail class were C4-AHL, C6-AHL, A11, A12, B12, and 
S4 (Tables 2 and S3). In this class, the most potent was the 8-atom tail sulfonamide analog of the native ligand 
C8-AHL, A12 (Inh % = 68, IC50 = 0.38 μM). The 7-atom sulfonamide A11 was also a CepR antagonist, although 
100-fold less potent than A12. The lead CepR antagonists in the PHL class were C8, C14, E3, E5, and E10, with 
the most potent PHLs displaying low micromolar IC50 values (Table 2). Having a substituent on the PHL aryl 
ring was critical to activity, as the unsubstituted PHL (and natural signal) C1 was inactive, paralleling the lack of 
agonistic activity for the unsubstituted PPHL B9 (see above). However, for at least the PHLs tested here, neither 
the position nor the nature of the substituent on the PHL aryl group appeared to dramatically impact activity, 
ranging from electron-withdrawing (-Cl, C6) to electron-donating (-SCH3, E7), although PHLs with fluorine in 
any position were inactive as antagonists (e.g., C2, C3, and C4; Table S3). The 3-nitro PHL C14 was among our 
most potent CepR antagonists; we previously have found C14 to display a diverse range of activities in LuxR-type 
receptors, ranging from being a highly potent agonist in LuxR (V. fischeri)25 and ExpR2 (P. carotovora)27 to a 
potent antagonist in LasR (P. aeruginosa)25. Intriguingly, we found that analogs of C14 with alternative head 
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groups exhibited dramatic losses in activity (e.g., thiolactone F10, cyclopentyl F18, phenyl F25, ethyl ester F40, 
and nitro-phenyl F55 analogs; Table S3). This trend suggests that the HL headgroup may be key to CepR antago-
nism by at least this PHL scaffold.
evaluation of lead cepR modulators in a member of the Bcc. We next sought to assess if the CepR 
modulators identified in the Ec-reporter maintained their activities in a member of the Bcc. For these studies, we 
generated a B. multivorans cepI::lacZ reporter organism (Bm-reporter) using standard allelic exchange methods 
(see Methods). Along with B. cenocepacia, B. multivorans is one of the most commonly isolated Bcc members6,44. 
We note that small molecules must contend with a different cellular environment in the native organism relative 
to E. coli48; however, as both CepR and the cepI promoter are highly conserved among Bcc species (Fig. S3), we 
reasoned that the majority of compounds identified in the Ec-reporter (containing B. cenocepacia versions of 
the cepI promoter and the cepR gene) would maintain their relative activity profiles in CepR in B. multivorans. 
Our Bm-reporter organism had a genomic replacement of its synthase gene cepI with lacZ, resulting in a tran-
scriptional fusion of the cepI promoter region with lacZ that encodes β-galactosidase. Similar to the Ec-reporter, 
CepR binding to the cepI promoter then induces β-galactosidase production, allowing for the quantitation of 
CepR activity. Using the Bm-reporter organism, we observed robust activity for CepR in response to C8-AHL 
(EC50 = 0.7 nM, Table 3).
We screened the most potent AHLs identified in the Ec-reporter in this new Bm-reporter. Structures of the 
lead CepR agonists and antagonists identified are shown in Fig. 2A,B, and the SAR trends are summarized in 
Fig. 2C,D. The PPHLs retained the strongest CepR agonistic activities in the Bm-reporter overall (E37 > E35 > 
E32 > E33 > B7 > E30 ≈ E26 ≈ C8-AHL). Most notably, we found para-nitro substituted PPHL E37 especially 
potent in the Bm-reporter, with an EC50 ~250-fold lower than C8-AHL (Act % = 91, EC50 = 0.0025 nM). This 
potency improvement relative to the native ligand is notable and represents the largest increase, along with the 
lowest EC50 value overall (single digit picomolar), that we have measured in any LuxR-type receptor so far. When 
looking at overall potency trends between the Bm- and Ec-reporters, we note that the EC50 values were lower in 
the native organism; for example, the native ligand C8-AHL has an EC50 of 0.70 nM in the Bm-reporter, but has 
a ~10-fold higher EC50 (5.7 nM) in the Ec-reporter. PPHL E34 remained a potent agonist; however, its activity 
was much closer to that of C8-AHL in the Bm-reporter. Of the agonists tested in both reporter assays, only the 
potencies of 3’OH-C8-AHL, 3’O-C8-AHL, E31, and E36 were dramatically reduced in the Bm-reporter relative 
to the Ec-reporter.
Turning to the CepR antagonism data in the Bm-reporter, of the 10 most potent antagonists uncovered using 
the Ec-reporter, seven compounds remained in the top 10 in the Bm-reporter: A12, B12, C8, C14, E3, E7, and 
E25 (Table 4). C4-AHL and the cyclopentyl HL B12 were among the most potent antagonists in the Bm-reporter, 
supporting again that short-alkyl tails lead to CepR antagonism by AHLs. 3’-O-C6-AHL, the sole 3-oxo com-
pound to have any activity in CepR, and the sulfonamide analog of C8-AHL, A12, both retained strong antagonis-
tic activity in CepR. Likewise, PHLs C14, C8, E3, and E25 remain potent antagonists for CepR in B. multivorans. 








C4-AHL 58 20c 15–28
C6-AHL 83 7.5 5.7–9.8
3’O-C8-AHL 71 16d —
A11 78 11 h 5.1–22
A12 68 0.38c 0.10–1.2e
B12 69 3.7c 2.7–5.2
C6 66 39c 26–63
C1 8 — —
C7 89 5.9d —
C8 79 2.7c 2.1–3.5
C14 46 1.4 0.30–11e
E3 77 3.3c 2.2–5.7
E5 81 2.7 1.2–10
E7 76 3.1c 2.2–4.4
E10 79 0.43c 0.20–1.1e
E25 70 3c 2.2–4.5
S4 72 32 18–63
Table 2. CepR antagonism data for selected compounds in the E. coli reportera. aCompounds were evaluated in 
E. coli reporter strain JLD271 [pJN105-cepR + pSC11-cepI]. Activity for 100 μM C8-AHL set to 100%. All assays 
n ≥ 3. Maximal activation error = ±10%. See Methods for full details of assay methods. bCI = 95% confidence 
interval for IC50 value. cDose–response antagonism curve showed inversion to agonism (i.e., non-monotonic 
behavior) at high compound concentrations. Concentrations at which CepR agonism was observed were 
excluded from IC50 calculations. See SI for additional details. dCurve did not reach minimum plateau. e|Hill 
slope| < 1.0, which affected 95% CI.
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able to bring reporter activity down to nearly zero in the Bm-reporter, with 3-bromo C8, 4-nitro C13, 3-CF3 E3, 
and 3-SMe E7 among the most potent of this group. Overall, our screening data in the two reporter systems, 
each with different CepR receptors, suggest that ligands identified as active in one CepR receptor can be utilized 
to modulate other CepR homologs. These data also validate the use of the heterologous strain to identify CepR 
ligands that maintain their activity profiles in a native Bcc species.
Swimming motility assays in B. multivorans. We were interested to assess the effects of our lead CepR 








C8-AHL 100 0.70 0.030–2.3c
3’OH-C8-AHL 78 ≥980d —
3’O-C8-AHL 72 ≥3500d —
B7 82 0.24 0.11–0.64c
CL 80 940 —
E26 96 0.60 0.1–69c
E30 84 0.75 0.26–2.3c
E31 78 ≥3400d —
E32 110 0.080 0.029–0.24c
E33 94 0.15 0.028–0.56c
E34 110 0.94 0.45–2.1c
E35 98 0.022 0.0062–0.067c
E36 100 ≥3900d —
E37 91 0.0025 0.00020–0.0090c
Table 3. CepR agonism data for selected compounds in the B. multivorans reportera. aCompounds were 
evaluated in reporter strain B. multivorans cepI::lacZ. Activity for 100 μM C8-AHL set to 100%. All assays n ≥ 3. 
Error = ±10%. See Methods for full details of assay methods. bCI = 95% confidence interval for EC50 value. 
c|Hill slope| < 1.0, which affected 95% CI. dDose-response curve did not reach maximum plateau.
Figure 2. Selected CepR modulators and SAR synopsis. Lead CepR modulators and SAR for CepR (A) agonism 
and (B) antagonism. (C) Schematic indicating key features of the AHL scaffold that agonize CepR. Red indicate 
features found in all agonists. Blue indicates features of the strongest agonists. Green indicates native ligand. 
(D) Schematic indicating key features of the AHL scaffold that antagonize CepR. Red indicates features vital 
to antagonism. Blue indicates the sulfonamide scaffold. Green indicates the PHL scaffold. Brown indicates the 
cyclopentyl scaffold.
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to directly link CepR activity in B. multivorans to any QS-controlled phenotype. Motility has been shown to be 
controlled partially (B. cenocepacia)49 or completely (B. cepacia K56-2)50,51 by the CepI/CepR system in other 
Bcc members, and the B. multivorans organism has been shown to be motile52. Therefore, we chose to study the 
effects of compound treatment on both the swarming and swimming motility of B. multivorans (B. multivorans 
ATCC17616; see Methods).
Swarming motility (on 0.5% agar52) was not increased upon addition of C8-AHL, suggesting swarming is not 
under the direct control of CepI/CepR in B. multivorans (Fig. S4). In contrast, we found that under our swimming 
conditions (on 0.3% agar), the addition of native ligand C8-AHL increased swimming radius in both the parental 
and cepI::lacZ organisms (Figs 3 and S4), suggesting swimming motility is at least partially under the control of 
CepI/CepR in B. multivorans. We then tested the ability of our non-native compounds to modulate swimming 
motility in B. multivorans. Motility increased upon treatment by three of our most potent CepR agonists, E32 
(195%), E35 (175%), and E37 (173%), which was comparable to that by the native signal C8-AHL (182% relative 
to untreated sample, Fig. 3). In contrast, treatment with some of our strongest CepR antagonists, A12, B12, and 
E3, significantly decreased motility (55%, 53%, and 58%, respectively, relative to untreated sample). These results 
support that swimming motility in B. multivorans is at least partially under the control of the CepI/CepR QS 
system and that our compounds can be used to alter this behavior.
B. multivorans infection assays in C. elegans. We next assessed the effects of our lead CepR modulators on 
exacerbating or alleviating infections by a Bcc member using the nematode C. elegans as a model of pathogenicity. 
We infected N2 nematodes with B. multivorans ATCC17616 in the presence of compound, and assessed survival of 
worms over time (see Methods)13,35,53. None of the compounds tested caused measurable toxicity effects in unin-
fected worms under these conditions. Addition of CepR’s native ligand (C8-AHL) to Bm-infected worms significantly 
increased worm death relative to untreated worms (Fig. 4, p < 0.0001). Furthermore, addition of our strong CepR 
agonist E37 promoted worm killing in B. multivorans infected worms in a similar manner (p < 0.0001). Weak CepR 
agonist H2, however, did not appear to affect worm survival under these conditions (Fig. S5, p = 0.69). Strikingly, 
many of the most potent CepR antagonists prolonged nematode survival; we show representative examples in Fig. 4 
(C8, B12, and E3; for full set of survival assay data, see Fig. S5). Several previous studies, using genetic approaches, 
have demonstrated the importance of QS to pathogenicity in nematode infections in other members of the Bcc13,54. 
Our results here, using chemical CepR modulators, appear to replicate these effects in B. multivorans nematode infec-
tions. These data support chemical inhibition of CepR as a route to strongly attenuate virulence in a Bcc member.
Discussion
Chemical strategies to modulate CepR-mediated QS in Bcc species would provide an approach to study the role of this 
signaling process in Bcc infections with both spatial and temporal control. Such chemical approaches are scarce, how-
ever, and no synthetic antagonists that both directly target CepR and also affect QS-controlled phenotypes have been 
reported to date. Here, we report CepR agonism and antagonism data for a library of synthetic AHL analogs obtained 
using both an E. coli reporter and a B. multivorans reporter. These small molecule screens identified a set of highly 
potent CepR activators and inhibitors. Furthermore, our lead compounds have the ability to alter QS-controlled 
phenotypes in wild-type B. multivorans—namely swimming motility and the survival of infected nematodes—in a 








C4-AHL 76 0.25c 0.065–0.57d
C6-AHL 20 — —
3’O-C6-AHL 85 0.80 0.20–62d
A12 82 1.7 0.93–3.0
B12 83 2.1 1.1–3.3
C8 94 2.6 1.2–4.5d
C13 96 3.6 1.5 to 95d
C14 54 0.62 0.30–1.5d
E3 100 1.9 1.1–3.9
E5 43 — —
E7 97 4.0 2.2–13d
E10 21 — —
E13 13 — —
E25 83 3.3 2.0–8.4
S4 93 3.7 1.5–2d
Table 4. CepR antagonism data for selected compounds in the B. multivorans reportera. aCompounds were 
evaluated in reporter strain B. multivorans cepI::lacZ. Activity for 100 μM C8-AHL set to 100%. All assays 
n ≥ 3. Error = ±10%. See Methods for full details of assay methods. bCI = 95% confidence interval for IC50 
value. cDose–response antagonism curve showed inversion to agonism (i.e., non-monotonic behavior) at high 
compound concentrations. Concentrations at which CepR agonism was observed were excluded from IC50 
calculations. See SI for additional details. d|Hill slope| < 1.0, which affected 95% CI.
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are apparent (Fig. 2C,D). The most potent agonists contain aryl tail groups with various substitution patterns on the 
phenyl ring and a 2-carbon linker between the aryl ring and the amide bond. Among this class, the PPHL class stood 
out as a lead scaffold for CepR agonism. In turn, the most active CepR antagonists have an overall shorter acyl tail 
than the native ligand, C8-AHL, with various tail substituents, including aliphatic and phenylacetanoyl groups.
These SAR data for AHLs allowed us to consider potential mechanisms of action for their CepR agonism and 
antagonism. Agonism is perhaps the most straightforward to rationalize, as it is likely that these AHL deriva-
tives act upon the same ligand-binding site in CepR as the native signal, C8-AHL. The only structural data of a 
C8-AHL-interacting LuxR-type receptor is for CepR2, consisting of an X-ray structure of its AHL-free, or “apo” 
ligand-binding domain55. Glycerol was found to be present in CepR2’s putative AHL-binding site and engaged 
with two key residues (Thr 130 and Asp 76) that have been found to be important for AHL binding in other 
LuxR-type receptors. In view of this similarity, we hypothesize that CepR binds C8-AHL and our non-native ago-
nists using the same, conserved subset of amino acids as other LuxR-type receptors. We predict that CepR:AHL 
Figure 3. B. multivorans motility assay data. Swimming motility was measured by spotting B. multivorans plus 
compound indicated in the center of M9 + 0.1% casamino acids + 0.3% agar in a 10 cm diameter petri dish. 
Area of the colony after 72 h incubation was calculated using ImageJ, normalized to the B. multivorans wild-
type + vehicle (DMSO), and listed above each plate shown.
Figure 4. C. elegans infection assay data. Survival analysis of B. multivorans (Bm)-infected C. elegans N2 with 
treatment of the compound as indicated. For both plots, red lines indicate C8-AHL treatment, black lines 
indicate vehicle (DMSO) treatment, gray lines indicate compound treatment (lines overlap) but no bacteria. See 
Fig. S5 for full data and statistical analyses. (A) Survival plots of Bm-infected worms in the presence of strong 
agonist E37 (green). (B) Survival plots of Bm-infected worms in the presence of antagonists C8 (green), B12 
(blue) or E3 (yellow).
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binding then leads to conformational changes within the protein to elicit homodimerization and downstream 
gene activation (similar to other LuxR-type receptors; see Fig. 1), and the 7–8 atom acyl chain length in our top 
CepR agonists is ideal for promoting such AHL-mediated CepR activation.
The mechanism of action for the CepR antagonists, however, remains ambiguous. The overall tail length of our most 
potent CepR antagonists was comparatively shorter than the native ligand. Plus, we observed that potent agonists could 
switch to antagonists by the subtraction of one carbon from the acyl chain (B7 vs. Control 7, E31 vs. C8, E37 vs. C13, 
E38 vs. C14, and E36 vs. E3 (Tables 1 and 2). These data suggest our antagonists may compete with the native ligand in 
binding CepR, yet upon binding cause different interactions that block activation. From here, whether the mechanism 
of CepR inhibition by these compounds is one of protein destabilization, as previously seen with LasR56 and QscR57 
in P. aeruginosa, or protein stabilization in such a way as to inhibit its ability to bind DNA, as demonstrated with CviR 
from C. violaceum58, or a combination of pathways or a new pathway entirely, will require further experimentation.
To close, the compounds identified herein constitute new chemical tools to study QS in Bcc species in a variety of 
contexts. Given the strong conservation of CepR between Bcc members, we hypothesize our compounds will main-
tain their activity profiles across Bcc member species and we can begin to use them to assess the role of CepI/CepR 
QS on a broader scale. In addition, these compounds could prove useful when investigating polymicrobial infections 
involving Bcc members; for example, co-infections between P. aeruginosa and Bcc species in the CF lung. A next 
step moving forward will be to gauge the selectivity of the ligands identified herein for CepR over other LuxR-type 
receptors. When comparing the activities of our lead compounds in CepR vs. the three LuxR-type receptors in P. 
aeruginosa (i.e., LasR, RhlR, and QscR)22,24,59, our preliminary analyses show that agonist E37, and antagonists A12 
and E3 are selective for CepR over these receptors. Such compounds could allow for the selective targeting of QS in 
one organism in a mixed culture over time and allow for insights into the potential for interspecies interactions via 
QS and their effects on host health outcomes. Ongoing studies are focused in this arena, along with further deline-
ating the mechanisms by which our CepR ligands agonize and antagonize CepR, and will be reported in due course.
Methods
Bacterial strains and growth conditions. The bacterial strains and plasmids used in this study are 
summarized in Table S3. All biological media and reagents were obtained from commercial sources and used 
according to the manufacturer’s instructions. E. coli JLD271, E. coli OP50, and B. multivorans were grown in LB 
(Research Products International) at 37 °C with shaking (at 225 rpm). Bacterial growth was assessed by measur-
ing the culture absorbance at 600 nm (OD600) using a Biotek Synergy 2 microplate reader operating Gen5 data 
analysis software. The E. coli reporter was grown in Luria Bertani (LB) medium containing 100-μg/mL ampicillin 
and 15-μg/mL gentamicin. The B. multivorans reporter was also grown in LB medium. Freezer stocks of bacterial 
strains were maintained at −80 °C in 1:1 LB:glycerol. C. elegans N2 was propagated under standard conditions, 
synchronized by hypochlorite bleaching, and cultured on nematode growth medium using E. coli OP50 as a food 
source, as described previously53.
chemicals, reagents, and compound handling. The non-native AHLs examined in this study 
were synthesized and purified as described previously24,25,37,46,59,60. The structures of all of the compounds are 
shown in Fig. S1. C4-AHL, C6-AHL, 3’O-C6-AHL, C8-AHL, 3’O-C8-AHL, 3’O-C12-AHL were purchased from 
Sigma-Aldrich. Chlorophenol red-β-D-galactopyranoside (CPRG), the substrate for the β-galactosidase assays, 
was purchased from Santa Cruz Biotechnology, Inc. All enzymes were purchased from New England Biolabs and 
used according to manufacturer’s instructions. Water (18 MΩ) was purified using a Millipore Feed System. Stock 
solutions of compounds were prepared in DMSO and stored at −20 °C in sealed glass vials. Final DMSO con-
centrations per well in biological assays did not exceed 1% (v/v). No compound had an effect on bacterial growth 
over the concentrations tested as gauged by monitoring OD600 over the time course of the assays.
ec-reporter plasmid construction. The pSC11-cepI reporter plasmid was constructed from pSC11-L39, 
using B. cenocepacia genomic DNA as a template (ATCC BAA-245D-5). Primers (9-SalI-cepI*-F and 
10-BamHI-cepI’-R) containing restriction sites for SalI and BamHI were used to amplify the cepI genomic 
region using OneTaq, digested with SalI and BamHI, and cloned into pSC11 digested with the same enzymes 
using Quick Ligase. pSC11-cepI was sequence verified. The pJN105-cepR plasmid was constructed by modifying 
pJN105-L40. Primers (7-EcoRI-cepR-F and 8-XbaI-cepR-R) containing EcoRI and XbaI restriction sites were used 
to amplify cepR from B. cenocepacia genomic DNA (ATCC BAA-245D-5). The PCR product was digested with 
XbaI and EcoRI, then cloned into pJN105-L digested with the same enzymes using Quick Ligase. This plasmid 
was sequence verified (see Table 3; primers 2-pBADprom-F, 13-cepR-R2, and 14-cepR-F2).
B. multivorans cepI::lacZ reporter organism construction. The B. multivorans cepI::lacZ strain was 
generated by replacing the native cepI with a promoterless lacZ. We first generated an intermediate plasmid, 
pEXG2 ΔcepI (Genscript), which had DNA fragments flanking cepI joined by two restriction enzyme recog-
nition sequences, xbaI and scaI. These sites were used to introduce Klenow-blunted XbaI- and AseI-cut lacZ 
from pUC18-miniTn7T-Gm-lacZ61. The generated pEXG2 PcepI::lacZ plasmid was mated into B. multivorans 
ATCC17616 using the E. coli strain RHO362, which requires diaminopimelic acid (DAP, added at 400 μg/mL final) 
for growth. B. multivorans exconjugants containing the chromosomally integrated pEXG2 PcepI::lacZ plasmid 
were isolated on LB agar plates using gentamicin at 300 μg/mL and no DAP for counterselection of E. coli. Strains 
in which the plasmid had excised were subsequently selected on no-salt LB agar plates containing 15% sucrose 
(no-salt LB agar plates containing 10 g bacto-tryptone, 5 g yeast extract, and 15 g agar/L of water). Mutants with 
the desired PcepI::lacZ allele were identified by the ability to turn blue on LB agar plates containing 40 μg/mL 
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (to measure CepR-induced β -galactosidase production) and 
10 μM C8-HSL (to activate CepR), and verified by PCR amplification and sequencing of the PCR products.
1 0Scientific RepoRtS |         (2019) 9:13449  | https://doi.org/10.1038/s41598-019-49693-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
E. coli β-galactosidase reporter method. E. coli β-galactosidase reporter assays (derived from ref.63) and 
reagents used to obtain primary screening and dose-response data were performed as previously described22,60,64, 
with the following modifications: E. coli JLD271 (∆sdiA) was co-transformed iteratively with pSC11-cepI and 
pJN105-cepR via electroporation. A single colony was used to start overnight cultures in LB medium + ampicil-
lin (100 μg/mL) + gentamicin (15 μg/mL). A 1:10 dilution of overnight culture was grown in fresh medium to 
OD600 = 0.25. A sterile solution of L-arabinose in water (27 mM final concentration) was added to induce protein 
expression, after which cells were plated in 96-well plates containing varying concentrations of compound (200 μL 
total volume).
Cells were grown for 4 h, OD600 was read, 50 μL aliquots from each well were permeabilized in 200 μL Z Buffer, 
and then 150 μL of this mixture used to measure the cleavage of 25 μL of 4 mg/mL CPRG in phosphate buffered 
saline (PBS) at 37 °C until positive control wells developed a deep red color (~30 min). For all agonism assays, 
synthetic compound (100 μM) was screened alongside and compared to the native ligand, C8-AHL (100 μM). For 
all primary and dose-response antagonism assays, the concentration of native ligand utilized was 10 nM (approx-
imately equal to twice its EC50 value). IC50 and EC50 values, as well as 95% confidence intervals, were determined 
from sigmoidal curve fits using GraphPad Prism software (v.7.02, dose-response data found in Figs S3 and S4) 
using a variable slope parameter. At least 3 separate trials were performed using unique cultures on separate days.
Burkholderia multivorans cepI::lacZ reporter assays. The B. multivorans cepI::lacZ strain was used 
to obtain dose-response data for CepR in response to synthetic AHLs. Overnight cultures of B. multivorans 
cepI::lacZ were grown in LB medium at 37 °C with shaking (225 rpm). Aliquots (200 μL) of a 1:10 dilution of 
this overnight culture were plated into 96-well plates containing varying concentrations of compound, and then 
grown for 4 h at 37 °C with shaking (225 rpm). β-galactosidase production was measured as described above for 
E. coli, with the following changes: permeabilized cells were incubated at 25 °C with substrate CPRG for ~10 min 
until positive control wells developed a deep red color. For agonism assays, synthetic compound was screened 
alongside and compared to the native ligand, C8-AHL (100 μM). For antagonism assays, the concentration of 
native ligand utilized was 5 nM (approximately equal to twice its EC50 value).
Motility assay. The motility assay was based on a previously reported procedure52. B. multivorans was grown 
overnight with 50 μM compound at 37 °C and normalized to OD600 = 0.4, and then cells were washed with ster-
ile water and resuspended with 50 μM fresh compound. Cells (5 μL) were spotted in the center of M9 + 0.1% 
Casamino Acids + 0.3% agar plates (100 mm diameter). Cells were grown for 72 h at 37 °C. Images were analyzed 
using ImageJ to calculate the area of the colony and normalized to the area of B. multivorans wild-type + vehicle 
(DMSO).
C. elegans survival assay. The C. elegans survival assay was based on previously reported procedures35,65. 
To synchronize worms, eggs were harvested by hypochlorite bleaching (5 min in 1 mL 5% bleach, 0.25 mL 5 M 
NaOH, 3.75 mL H2O), and grown on Nematode Growth Media (NGM) + E. coli OP50 at 21 °C. B. multivorans 
was grown overnight with the compound of interest in LB medium (1 μM for agonists, 50 μM for antagonists), 
and then the overnight culture was centrifuged, resuspended in the assay medium, standardized to OD600 = 0.8, 
and 25 μL of this culture was used per condition. CFUs of these standardized cultures were used to confirm that 
bacteria numbers were relatively the same. For the survival assay, synchronized worms (L4 stage) were suspended 
in liquid NGM media containing bacteria and compound in 96-well plates (100 μL total volume). In all cases, 
DMSO volume did not exceed 1% of total volume. Plates were incubated at 25 °C, after which they were analyzed 
by a dissecting microscope. The fraction of dead worms was determined by scoring the number of dead worms 
and the total number of worms in each well. At least 30 nematodes were used for each well, and each assay was 
performed at least in duplicate on a single day (n ≥ 60). Survival assays were then repeated at least once on differ-
ent days to verify patterns. Compound effect on worm survival rarely varied between replicates, but the overall 
worm susceptibility varied among assays. Kaplan-Meier survival curves were calculated using GraphPad Prism 
(v. 7.0) software.
Data Availability
The datasets generated and analyzed during the current study are available from the corresponding author upon 
reasonable request.
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